The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

December 8, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) commonly develop skin lesions related to anti-tumor necrosis factor (anti-TNF) medications, according to a retrospective study.

You Might Also Like
  • Skin Complications of Anti-TNF Therapy Common in IBD
  • Skin Exam Advised Before Anti-TNF-Alpha Therapy
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease

“We were most surprised by the relatively high percentage (30%) of patients developing skin problems while being treated with anti-TNF agents,” Dr. Isabelle Cleynen from KU Leuven, Belgium, tells Reuters Health by email. “Not all skin problems were equally severe, though, and most patients had a good response to treatment of their skin problem.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Psoriasiform skin manifestations have been reported as adverse events associated with anti-TNF therapy, but other skin lesions associated with these treatments have not been well characterized.

Dr. Cleynen and colleagues describe skin lesions that developed in association with anti-TNF treatment in a retrospective study of 917 patients with IBD.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, 264 patients (29%) developed skin lesions a median 11.6 years after diagnosis of IBD and 1.9 years after initiation of anti-TNF treatment. More women (31%) than men (26%) developed skin lesions.

The risk of developing skin lesions was 31% among patients carrying one to four risk variants for the subset of single-nucleotide polymorphisms showing at least nominally significant association with lesion development and 48% for those carrying more than four such risk variants.

Infliximab doses and trough levels were similar in patients with and without skin lesions, and development of lesions did not seem to be associated with an apparent reduction in infliximab effectiveness.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The most common lesion types were psoriasiform eczema (81 patients, 30.6% of those with lesions), eczema (62 patients, 23.5%), xerosis cutis (28 patients, 10.6%), palmoplantar pustulosis (14 patients, 5.3%) and psoriasis (10 patients, 3.8%), all of which are illustrated in the report, online Dec. 8 in Annals of Internal Medicine.

The extremities, face and trunk were most commonly affected. In contrast, the scalp and pubic regions were more often affected by skin lesions not related to anti-TNF therapy.

Most patients responded to dermatological treatment, although 10.6% of those with skin lesions discontinued anti-TNF treatment because of the lesions.

“The best advice our dermatologists and gastroenterologists give to our patients is general preventive measures for dry skin (avoidance of a bath, no soaps but oils, hydrating creams, etc.), which in many cases seemed to be effective to resolve the skin problem,” Dr. Cleynen says.

“Of course, with our study set up, we cannot say how many patients would not have developed a skin problem, or would not have progressed from a dry skin to a more severe type of skin lesion when having taken preventive measures. But we are convinced that these preventive measures are important, and that they will help at least in a subset of patients,” she adds.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Anti-TNF, inflammatory bowel disease, infliximab, Psoriasis, rash, skin

You Might Also Like:
  • Skin Complications of Anti-TNF Therapy Common in IBD
  • Skin Exam Advised Before Anti-TNF-Alpha Therapy
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Statin Use Tied to Lower Risk of Inflammatory Bowel Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)